Annovis Bio (ANVS) Enterprise Value (QoQ) (2020 - 2026)
Annovis Bio (ANVS) Enterprise Value (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.30% |
| Dec 31, 2025 | -27.66% |
| Sep 30, 2025 | 10.53% |
| Jun 30, 2025 | 23.10% |
| Mar 31, 2025 | -110.73% |
| Dec 31, 2024 | 16.50% |
| Sep 30, 2024 | -215.92% |
| Jun 30, 2024 | -29.03% |
| Mar 31, 2024 | 46.13% |
| Dec 31, 2023 | -48.58% |
| Sep 30, 2023 | 75.37% |
| Jun 30, 2023 | 4.89% |
| Mar 31, 2023 | 41.74% |
| Dec 31, 2022 | 11.28% |
| Sep 30, 2022 | 11.08% |
| Jun 30, 2022 | 15.69% |
| Mar 31, 2022 | 6.60% |
| Dec 31, 2021 | 3.73% |
| Sep 30, 2021 | 3.59% |
| Jun 30, 2021 | -778.56% |